Exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancer
Abstract Background Tyrosine kinase inhibitors (TKIs) are a class of molecular targeted drugs designed to selectively inhibit tyrosine kinase activity associated with oncogenic signaling pathways and drivers, and have emerged as key therapeutic agents for colorectal cancer (CRC). The purpose of this...
Saved in:
| Main Authors: | Xiaosong Li, Zhenlong Chen, Jie Yin, Xiping Shen, Hang Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14639-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer
by: Faris Alrumaihi, et al.
Published: (2025-06-01) -
Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01) -
Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors
by: Nikhil Vojjala, et al.
Published: (2025-01-01) -
Establishment of in vitro Src tyrosine kinase inhibitors screening model
by: WANG Chen-hui, et al.
Published: (2007-11-01) -
Novel Insights Into Receptor Tyrosine Kinases in Pulmonary Arterial Hypertension
by: Wenze Wu, et al.
Published: (2025-08-01)